Neurocrine Biosciences
NBIX
266 hedge funds and large institutions have $7.63B invested in Neurocrine Biosciences in 2018 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 103 increasing their positions, 88 reducing their positions, and 36 closing their positions.
17% more call options, than puts
Call options by funds: $68.8M | Put options by funds: $58.6M
17% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 88
5% more capital invested
Capital invested by funds: $7.29B → $7.63B (+$347M)
3% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 36
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% less funds holding
Funds holding: 267 → 266 (-1)
3.01% less ownership
Funds ownership: 106.18% → 103.16% (-3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$143M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$59.6M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$55.5M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$48M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$70.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$65.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$60.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$48.1M |
| 5 |
Millennium Management
New York
|
-$34.3M |
NBIX Hedge Fund Activity: Q1 2018 in Review
266 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2018, worth a combined $7.63B — up 4.8% from $7.29B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new NBIX positions and 36 closed out — a net gain of 1 holder — while 103 added to existing stakes and 88 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $143M. The largest seller was HealthCor Management, cutting an estimated $70.4M.
- 266 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2018, down from 267 in Q4 2017.
- Funds reported $7.63B of Neurocrine Biosciences stock for Q1 2018, up 4.8% quarter-over-quarter.
- 37 funds opened new Neurocrine Biosciences positions in Q1 2018 and 36 closed out, a net change of +1 holder.
- The largest Neurocrine Biosciences buyer in Q1 2018 was Janus Henderson Group, an estimated $143M added.
- The largest Neurocrine Biosciences seller in Q1 2018 was HealthCor Management, an estimated $70.4M sold.
Based on aggregated 13F filings for Q1 2018.